Fostamatinib

BreastfeedingPediatric
  • TRADE NAME: Tavalisse (Rigel)
  • INDICATIONS: Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment
  • CLASS: Spleen tyrosine kinase (Syk) inhibitor
  • HALF-LIFE: ~15 hours

FDA APPROVAL DATE: 04/17/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Strong CYP3A4 inhibitors or inducers

PREGNANCY CATEGORY: N/A
Based on animal studies, can cause fetal harm

Our database has 27 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTHER


Page last updated 05/01/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric